Relative to microarrays, RNA-seq has been reported to offer higher precision estimates of transcript abundance, a greater dynamic range, and detection of novel transcripts. However, previous comparisons of the 2 technologies have not covered doseresponse experiments that are relevant to toxicology. Male F344 rats were exposed for 13 weeks to 5 doses of bromobenzene, and liver gene expression was measured using both microarrays and RNA-seq. Multiple normalization methods were evaluated for each technology, and gene expression changes were statistically analyzed using both analysis of variance and benchmark dose (BMD). Fold-change values were highly correlated between the 2 technologies, whereas the −log p values showed lower correlation. RNA-seq detected fewer statistically significant genes at lower doses, but more significant genes based on fold change except when a negative binomial transformation was applied. Overlap in genes significant by both p value and fold change was approximately 30%-40%. Random sampling of the RNA-seq data showed an equivalent number of differentially expressed genes compared with microarrays at ~5 million reads. Quantitative RT-PCR of differentially expressed genes uniquely identified by each technology showed a high degree of confirmation when both fold change and p value were considered. The mean dose-response expression of each gene was highly correlated between technologies, whereas estimates of sample variability and gene-based BMD values showed lower correlation. Differences in BMD estimates and statistical significance may be due, in part, to differences in the dynamic range of each technology and the degree to which normalization corrects genes at either end of the scale.
Dose response is the mainstay of toxicology, and as the costs associated with transcriptomic technologies have declined, the incorporation of multiple doses into the experimental design has become standard. With multiple doses, toxicogenomic studies have been able to evaluate dose-dependent transitions in mechanism (Andersen et al., 2008 (Andersen et al., , 2010 , cross-species differences in chemical potency and mode of action (Black et al., 2012; Kopec et al., 2012; Thomas et al., 2013a) , dose-dependent concordance between apical and transcriptional responses (Bercu et al., 2010; Thomas et al., 2011 Thomas et al., , 2012 Thomas et al., , 2013b , and ligand-dependent differences in potency and potential modes of action (Hester et al., 2012; Naciff et al., 2005) . As the interpretive tools and underlying biological knowledge continue to mature, dose-response studies in toxicogenomics will become even more useful in understanding the potential adverse effects of chemicals.
Whole genome microarrays provide an estimate of gene transcript abundance, which is then used for statistical significance testing of different treatment conditions as well as estimates of the magnitude of the change in expression (Chen et al., 2012) . Microarrays have advantages in speed and ease of sample preparation, low per sample cost, and well-established protocols and methods for data analysis and data normalization (Shi et al., 2010) . However, microarrays also have limitations. Microarrays have a finite dynamic range due to the limitations of fluorescence and saturation of binding sites within the probe sets printed on the microarray. At low levels of expression, microarrays often have poor resolution of transcript binding due to high background effects and nonspecific binding.
Whole transcriptome, next-generation sequencing (RNAseq), offers an alternative method for estimating transcript abundance in gene expression studies. RNA-seq has the potential to overcome many of the limitations associated with microarrays as it does not rely on predetermined probe sequences for expression measurements, and it is based on simple counting of reads that can be reliably aligned to a reference sequence. As count data, RNA-seq has effectively no limit to the dynamic toxicological sciences 137(2), 385-403 2014 doi:10.1093/toxsci/kft249 Advance Access publication November 5, 2013 range of signal detection, and, in theory, it can provide a higher degree of accuracy and precision in estimating relative expression levels. However, RNA-seq data also has potential challenges which remain less well explored. Reliable quantification of expression levels appears highly dependent on read depth, and low transcript abundances are characterized by high variance. Thus, the effective or useful lower limit of the dynamic range of RNA-seq is not clear. Additionally, methods for normalization and statistical analysis of RNA-seq data are less mature, and no established best practices exist for RNA-seq data analyses.
In this study, we directly compare gene expression data generated by microarray and RNA-seq for the same set of RNA samples isolated from the livers of rats treated for 13 weeks in a 5-point dose response to bromobenzene (BRBZ) (Dodd et al., 2013; Thomas et al., 2013b) . Expression measurements were conducted using Affymetrix HT Rat230+PM microarrays and ABI SOLiD 50bp single-read RNA-seq. The data generated by microarray and RNA-seq were normalized using several different methods to ensure broad applicability and statistically analyzed using ANOVA and benchmark dose (BMD) methods. Random sampling of the RNA-seq data at multiple read depths was used to evaluate the number of reads required to provide an equivalent number of differentially expressed genes compared with microarrays. Differentially expressed genes uniquely identified by both technologies were evaluated using quantitative reverse transcription-PCR (qRT-PCR).
MATeRiAls AND MeTHODs
Animals and treatment. BRBZ (CAS no. 108-86-1; Purity 99%; Catalog no. AC10668-0010) was purchased from Acros Organics through Fisher Scientific (Pittsburg, Pennsylvania). The corn oil vehicle (Catalog no. 700000-134) was purchased from VWR Scientific (Radnor, Pennsylvania). Details of the animal study have been published previously (Dodd et al., 2013) . Briefly, 5-to 6-week-old male F344/DuCrl rats (Charles River Laboratories, Kingston, New York) were exposed to 5 doses of BRBZ by gavage for 13 weeks (25, 100, 200, 300 , and 400 mg/kg). Gavage exposures were administered 7 days per week in a volume of 5 ml/kg of corn oil. A vehicle control group was run concurrently.
Animal use in this study was approved by the Institutional Animal Use and Care Committee of The Hamner Institutes for Health Sciences and was conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. Animals were housed in fully accredited American Association for Accreditation of Laboratory Animal Care facilities.
Necropsy and RNA isolation. Animal necropsy occurred within a few hours following the last gavage administration. Animals were weighed and anesthetized with a lethal IP injection of sodium pentobarbital. A cardiac puncture was performed to collect blood samples, and the animal was then exsanguinated via transection of the abdominal aorta. The liver was removed, and slices from each of the lobes were placed in RNAlater (Ambion, Austin, Texas).
Total RNA was isolated from 6 rats per dose from the RNAlater preserved tissues. Tissues were homogenized in TRIzol (Life Technologies, Carlsbad, California) . After homogenization, the samples were stored at −80°C until the remainder of the RNA isolation procedure was performed. Samples were thawed, centrifuged to remove debris, and loaded onto Phase Lock Gel tubes (5 PRIME, Gaithersburg, Maryland). The phase lock gel tubes were centrifuged, and the aqueous phase was used for RNA purification. RNA purification was performed using a QIAcube (Qiagen, Valencia, California) with the standard RNA protocol and RNeasy mini kits. Following purification, the quantity of RNA was determined spectrometrically, and the integrity of the RNA was evaluated with the Agilent 2100 Bioanalyzer (Palo Alto, California). The RNAs from the 5 animals with the highest RNA integrity numbers in each treatment group were selected for gene expression analysis using both microarrays and RNA-seq.
Gene expression microarray measurements. The gene expression microarray measurements have been described in a previous publication (Thomas et al., 2013b) . Briefly, double-stranded cDNA was synthesized for each of the 30 samples from 150 ng of total RNA, and biotin-labeled cRNA was transcribed using the IVT Express Kit (Affymetrix, Santa Clara, California). A total of 15 µg of labeled cRNA was fragmented, and a hybridization cocktail was prepared, plated, and loaded into an Affymetrix GeneTitan system. Hybridization was performed for 16 h on HT Rat230+PM microarrays. The GeneTitan system was used to perform the microarray hybridization, washing, and scanning. The gene expression microarray data can be downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (Accession no. GSE45892).
RNA-seq measurements. For each of the 30 samples, 65 µg of total RNA was further purified for polyadenylated RNA using the MicroPoly (A) Purist kit (Life Technologies) to obtain approximately 650 ng of polyA RNA. Two rounds of oligo dT column purification were performed on each sample. The absence of 18s and 28s ribosomal RNAs was assessed using the RNA Pico chip on the Agilent 2100 Bioanalyzer. If ribosomal RNA was present, a third round of oligo dT column purification was performed.
The polyA RNA samples were prepared for 50 base pair-single-read sequencing on the 5500xl Series SOLiD Next Generation Sequencer according to the protocol from the manufacturer's user guide (Life Technologies). A total of 150 ng of each polyA RNA sample was fragmented by chemical hydrolysis. RNA yield was quantified on a Qubit Fluorometer (Life Technologies), and the size distribution was assessed on an Agilent 2100 Bioanalyzer. The libraries for each sample were generated on the ABI Library Builder System (Life Technologies) using the whole transcriptome core kit for the 5500 Genetic Analysis System (Catalog no. 4472690, Life Technologies) and Agencourt RNA Clean XP beads (Beckman Coulter, Indianapolis, Indiana). The cDNA libraries were amplified and bar-coded using the SOLiD RNA Barcoding Kit (Module 1-96, Life Technologies). Following amplification, bar-coded libraries were purified 3 times with Agencourt RNA Clean XP beads and ethanol (Sigma-Aldrich, St Louis, Missouri). The concentrations of the samples were assessed with a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, Delaware), and the size distribution was assessed with the Agilent High Sensitivity DNA kit.
Libraries were immobilized onto the P1 beads during emulsion PCR (ePCR). During emulsion preparation, the libraries were diluted and pooled so that equal molar amounts of each bar code were present in the emulsion. The concentration of bar codes in the aqueous phase of the emulsion was 0.75pM. Following ePCR, the template beads were washed and enriched using the SOLiD EZ Bead Enricher, and the 3′ ends of the template beads were modified as instructed in the ABI SOLiD EZ bead Enricher user guide. The process was repeated 3 times to generate enough beads required for a full sequencing run. Beads were prepared and deposited onto 2 SOLiD 5500xl 6-lane flow cells. To increase read depth, 2 full sequencing runs (12 lanes) were performed.
RNA-seq mapping and data normalization. The sequencing data included 24 raw read files (6 lanes per flowcell, 2 flowcells per sequencing run, and 2 rounds of sequencing) grouped by sample and bar code. All reads with a base QC score of > 10 were mapped to the Ensembl Rat reference genome (Release 66.34) using LifeScope software (Version 2.5.1, Life Technologies). Cutoff filters for retained mapped reads included a mapping QV > 10, a minimum coverage > 3, and a minimum junction overhang > 8. Counts were summarized by genes and subsequently filtered to identify those genes where all 30 samples had a minimum raw count > 10 per gene. The raw and mapped sequencing data are available for download (http://www.thehamner.org/institutes-centers/ center-for-genomic-biology-and-bioinformatics).
Normalization of the sequencing data using reads per kilobase per million mapped reads (RPKM) was performed in Partek GS (Version 6.6, Partek Incorporated, St Louis, Missouri) with Ensembl annotation as reference. The normalized values were then matched to genes with minimum count > 10 and log 2 transformed. Normalization of the sequencing data by kernel density mean of M-component (KDMM) was performed in JMP Genomics 6 (SAS Institute, Inc., Cary, North Carolina). The normalized values were matched to include genes with a raw count > 10 and log 2 transformed. KDMM normalization utilized the gene-wise means across all samples as the baseline values and a grid size of (50, 50). The KDMM normalized data were also fit to a negative binomial model (KDMM-nb) as part of the ANOVA analysis in JMP Genomics. The raw count and normalized RNA-seq data are provided as Supplementary File 1.
Statistical analysis was performed on the normalized, log 2 -transformed data using ANOVA with pairwise contrasts between the vehicle control and each dose group. When p values were adjusted for multiple comparisons, the stepup false discovery rate (FDR) method of Benjamini and Hochberg (1995) was employed.
Microarray data normalization. Affymetrix CEL files were normalized using robust multiarray average (RMA) (Irizarry et al., 2003) in Partek GS 6.6, PLIER in BioConductor (R 2.15.1), and LOESS in JMP Genomics 6 (SAS Institute, Inc.). The LOESS normalization used an RMA background correction, LOESS normalization, and median polish feature summary. The normalized microarray data are provided as Supplementary File 2. Statistical analysis of the normalized microarray data was the same as that for the RNA-seq data.
Total and common gene set comparisons. In comparing the total gene set interrogated by each technology, the Ensembl Gene ID (Release 66.34) was chosen as the annotation feature for matching unique genes. Of the 31 402 probe sets on the microarray, there were a total of 323 promiscuous probe sets (ie, probe sets whose sequence interrogates more than 1 gene) and 11 285 unannotated probe sets. Of the unambiguously annotated probe sets, a total of 11 403 Ensembl Gene IDs were represented on the microarray. For the RNAseq data, a total of 9399 Ensembl Gene IDs had a minimum raw read count > 10 in all 30 samples.
Some of the analyses utilized a gene set that was common between the microarrays and RNA-seq data. In comparing the 11 403 microarray Ensembl Gene IDs and the 9399 RNA-seq Ensembl Gene IDs, a common gene set of 7890 Ensembl Gene IDs was utilized.
BMD analysis. The BMD analysis of the gene expression microarray and RNA-seq data was performed as described previously with some modification. The analysis was performed on the common gene set of 7890 Ensembl Gene IDs using BMDExpress (Version 1.41) . For both the microarray and RNA-seq data, normalized log 2 -transformed expression values for each gene were fit as continuous data to a series of 4 different dose-response models-linear, 2° polynomial, 3° polynomial, and power models. The power coefficient was restricted to ≥ 1 for the power model. Each model was run assuming constant variance, and the benchmark response (BMR) factor was set to 1.349 multiplied by the standard deviation in the control animals to estimate a BMD with a 10% increase in tail area . For model selection, a nested likelihood ratio test was performed on the linear, 2° polynomial, and 3° polynomial models. If the more complex model provided a significantly improved fit (p < 0.05), the more complex model was selected. If the more complex model did not provide a significantly improved fit (p ≥ 0.05), the simpler model was selected (Posada and Buckley, 2004) . The Akaike information criterion (AIC) for the selected polynomial model was then compared with the AIC for the power model. The model with the lowest AIC (Akaike, 1973) was selected as the final, best fitting model and was used to calculate a BMD and BMDL. To avoid model extrapolation and any potential bias from genes with poorly fitting models, genes with a BMD value greater than the highest dose or a goodness-of-fit p value < 0.1 were removed from further analysis. The Ensembl Gene IDs were then matched to their corresponding pathways using the GeneGo Metacore database (Minibase version 6.14.61644_4580, GeneGo, St Joseph, Michigan). Pathways with fewer than 5 genes with BMD value less than the highest dose and a goodness-of-fit p value > 0.1 were removed from the analysis. The median BMD was used to summarize each pathway.
Pathway enrichment analysis and hierarchical clustering. Gene set enrichment analysis was conducted for each technology and normalization method on all genes significant by p value < 0.01 and fold change > 1.5 or < −1.5 in at least 1 dose using the GeneGo pathway maps in the Metacore database (Version 6.5, build 62452, GeneGo). The enrichment p values were calculated based on a hypergeometric distribution with the GeneGo database used as the background. Significant enrichment was defined as a false discovery corrected p value < 0.05. Two-way hierarchical clustering was performed using Ward's method (JMP Genomics 6, SAS Institute, Inc.) on the −log 10 p values for pathways significantly enriched in at least 1 technology or normalization.
Quantitative RT-PCR. Genes were selected for quantitative RT-PCR analyses using the ANOVA results for the highest treatment dose (400 mg/kg-day). Significant genes were defined based on statistical significance (FDR < 0.05) in all 3 normalization methods or statistical significance (FDR < 0.05) in all 3 normalization methods and fold change > 1.5 in 2 of the 3 normalization methods. Due to the compression of fold-change values by the PLIER microarray normalization method and KDMM-nb RNA-seq normalization method, these normalization methods were disregarded when assessing fold change. The significant genes were sorted into 3 groups. Group 1 consisted of those genes that were significant by microarray analysis and not significant by RNA-seq analysis. A total of 41 genes met this criterion for FDR < 0.05 and 11 genes met this criterion for FDR < 0.05 and fold change > 1.5 (the 11 genes were a subset of the 41 genes). Group 2 consisted of genes that were significant by RNA-seq analysis and not significant by microarray analysis. A total of 24 genes met this criterion for FDR < 0.05 and 12 genes met this criterion for FDR < 0.05 and fold change > 1.5 (the 12 genes were a subset of the 24 genes). Group 3 consisted of genes that were significant by RNA-seq analysis and microarray analysis. A total of 24 genes met this criterion for FDR < 0.05 and 18 genes met this criterion for FDR < 0.05 and fold change > 1.5 (the 18 genes were a subset of the 24 genes). TaqMan quantitative RT-PCR assays were selected based on those that matched the same genomic transcript region in the RNAseq analysis as interrogated by corresponding probes in the Affymetrix Rat 230 probe set. A total of 90 assays were selected that corresponded to 90 genes from the 3 groups. Five endogenous control genes were added including tubulin alpha8 (Tuba8), ubiquitin c (Ubc), glyceraldehyde-3-phosphate dehydrogenase (Gaphd), phosphoglycerate kinase 1(Pgk1), and succinate dehydrogenase complex, subunit A (Sdha). The assays were ordered in 384-well microfluidic card format, which allowed 4 technical replicates of each assay. The default TaqMan control, 18s rRNA, was present on the microfluidic cards, but not used in any analyses.
Total RNA was isolated from the RNAlater preserved livers of 5 animals from the 400 mg/kg-day treatment group and 5 animals from the vehicle control group. The same 5 animals from each group were used for microarray, RNA-seq, and qRT-PCR measurements. RNA isolation was performed using a QIAcube (Qiagen) with the standard RNA Protocol and RNeasy mini kits. RNA quality was assessed spectrometrically and with the Agilent 2100 Bioanalyzer. A total of 2 µg of total RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, California). The TaqMan microfluidic cards were run according to the manufacturer's recommend protocol for moderately expressed genes. Briefly, 200 ng of cDNA per fill reservoir was combined with TaqMan Universal PCR Master Mix (Applied Biosystems). One sample was run per microfluidic card. The microfluidic card was centrifuged twice for 1 min at 1200 rpm (331 × g) and sealed. The microfluidic cards were run on an ABI 7900HT Real Time PCR instrument (Life Technologies).
The qRT-PCR data were normalized using the ΔΔCt method in the ABI ExpressionSuite software (Version 1.0.1, Life Technologies) using the geometric mean of 3 of the endogenous controls (Gapdh, Pgk1, and Sdha) as baseline.
One target gene (Src) and 2 endogenous control genes (Tuba8 and Ubc) were excluded from analysis due to poor amplification profiles in one or more samples. The direction of the differential expression (ie, up-or downregulated) was confirmed relative to the original measurements. Statistical significance was assessed using a one-tailed t-test at p < 0.01.
ResulTs

RNA-Seq Read Depth and Mapping Summary
Over the 30 samples, the average number of mappable reads was 20.8 million, of which 17.6 million (or 85%) mapped to annotated genes in the Ensembl 66.34 Rat reference genome (Supplementary File 3). The fewest mappable reads was for an animal in the 300 mg/kg-day group with 8.5 million reads mapped to exons. The largest number of mappable reads had nearly 27 million mapped to exons. Approximately 6% of reads mapped to introns and nearly 9% mapped as intergenic. The intergenic reads included those mapped to exons with an intronoverhang exceeding the minimum of 8 bp as specified in the mapping parameters. Among the 22 938 annotated rat genes, 11 580 had read counts greater than 0 in all 30 samples and 9399 genes had read counts greater than 10 in all 30 samples.
Rank Correlation of Expression Within and Between Technologies
The rank correlation between the number of raw sequencing reads and microarray intensities was between 0.662 and 0.674 (Table 1) . Following normalization, the rank correlation between RPKM normalized RNA-seq data and each of the microarray normalization methods was similar and ranged from 0.753 to 0.777. The rank correlation between KDMM normalized RNA-seq data and each of the microarray normalization methods was also similar, but consistently lower than that observed for RPKM normalized data and ranged from 0.643 to 0.674. Within technologies, the rank correlations were significantly higher. For RNA-seq, the rank correlations between RPKM and KDMM normalized data ranged from 0.879 to 0.887. The rank correlations within the microarray normalization methods ranged from 0.973 to 1.000.
Comparison of Differential Expression and Statistical Significance Across Technologies and Normalization Methods
To ensure a common basis for comparing differential expression and statistical significance for each technology, the microarray probe sets and RNA-seq data were both mapped to the Ensembl gene annotation. Of the 31 402 probe sets on the Affymetrix HT Rat230+PM microarray, 323 promiscuous probe sets (ie, probe sets whose sequence interrogates more than 1 Ensembl gene identifier) and 11 285 unannotated probe sets were removed from the analysis. A total of 11 403 Ensembl gene identifiers were unambiguously annotated on the microarray. For the RNA-seq data, a total of 9399 Ensembl gene identifiers had a minimum raw read count > 10 in all 30 samples. The overlap between the unambiguously annotated probe sets and the RNA-seq data was 7890 Ensembl gene identifiers.
Scatter plots of each pairwise comparison were constructed at the 400 mg/kg-day dose level (Fig. 1) . The fold-change values for genes exceeding a nominal fold-change cutoff of > 1.5 or < −1.5 showed a general linear relationship both within technology and between technologies. Within microarrays, the correlation coefficients for the different pairwise comparisons ranged from 0.949 to 0.999. The slope of the pairwise fold-change values suggests that the PLIER normalization method compresses the fold-change estimates relative to the other methods. Within RNA-seq, the correlation coefficients for the different pairwise comparisons ranged from 0.985 to 0.996. Similar to that observed with the PLIER microarray data, the slope of the pairwise fold-change values suggests that the KDMM-nb normalization method compresses the fold-change estimates relative to the other methods. In comparing across technologies, the average correlation coefficients for the different pairwise comparisons was 0.879 with a range between 0.850 and 0.902. In contrast to the fold-change values, scatter plots of the − log p values for genes exceeding a nominal cutoff of p < 0.01 showed a greater diversity in the degree of linear correlation across the 2 technologies and different normalization methods. Within microarrays, the correlation coefficients for the different pairwise comparisons were relatively high and ranged from 0.953 to 0.982. Within RNA-seq, the correlation coefficient for the KDMM and KDMM-nb comparison was 0.989, whereas the correlation coefficients for KDMM and KDMM-nb compared with RPKM were lower at 0.550 and 0.514, respectively. In comparing across technologies, the average correlation coefficient for the different pairwise comparisons was 0.407 with a range between 0.335 and 0.455.
In comparing the −log p values between the different RNAseq normalization methods, there appeared to be a bifurcation in the values when RPKM was compared with KDMM and KDMM-nb. Upon further investigation, it was determined that RPKM and KDMM normalization act differentially across the range of count data observed. KDMM normalizes the data by applying a kernel density weighted mean on the M-component from the trimmed mean of M values (TMM) (Robinson and Oshlack, 2010) . In essence, KDMM is adjusted by the weighted mean based on the kernel density estimation from the M-A plot. Because the data are log 2 transformed prior to constructing the M-A plot, the weighted mean adjustment is a weighted geometric mean in original count scale. In contrast, RPKM normalizes the data on an arithmetic scale by adjusting for total mapped reads, which is the product of the mean number of reads per gene and the total number of genes. Low count data generally tends to have larger arithmetic means than geometric means, whereas the opposite occurs for high count data. The effect of the differences in the normalization was most apparent in the 400 mg/kg-day treatment group (Fig. 2) . Upregulated genes are characterized by treatment samples possessing mapped read counts in excess of that observed in control samples, whereas the opposite is true for downregulated genes. With RPKM, this resulted in a substantial shift toward more upregulated genes ( Fig. 2A) because the effect of normalization tends to bias the estimate of high count treated data relative to controls compared with low count treated data relative to the same controls. The shift toward more upregulated genes was not observed with KDMM normalization (Fig. 2B) where the opposite shift might be expected if the differential affect of arithmetic versus geometric mean was equal across equal raw count ranges. The genes highlighted by the green points in the volcano plots had a mean raw read count among control samples of 11 267 and a mean raw read count of 8820 in the 400 mg/kg-day treatment samples. The genes highlighted by the red points had a mean raw read count among control samples of 1290 and a mean raw read count of 1868 in the 400 mg/kg-day treatment samples.
The differential effects of the normalization methods also lead to a divergence in the statistical significance. Statistical significance of differential expression is a function of the estimated t-statistic for each treatment (ie, log 2 fold change divided by the standard error). The shift toward upregulated genes in the RPKM normalization also inflates estimates of significance as it leads to greater positive t-statistics for upregulated genes (Fig. 2C , noted by the increased number of genes in quadrant 4 vs 1). The opposite occurs in the KDMM normalization, where downregulated genes tended to have smaller negative t-statistics (noted by the increased number of genes in quadrant 2 vs 3). Hence, those genes tended to have greater significance in KDMM than RPKM.
FiG. 2.
Volcano plots and t-statistic scatter plot comparing RNA-seq data normalized using RPKM and KDMM. A and B, Volcano plot of the RNA-seq data for the 400 mg/kg-day treatment group normalized using RPKM and KDMM. The data were analyzed using ANOVA linear contrast results for the 400 mg/ kg-day treatment group compared with vehicle controls. The analysis was performed on the common set of 7890 Ensembl gene identifiers. The red line indicates a p value cutoff of 0.01 (−log 10 p value = 2.0), and blue lines indicate fold-change cutoffs of > 1.5 or < −1.5. Genes are color coded as in (C). C, Scatter plot of log 2 t-statistics (log 2 fold change/standard error) for 2198 genes with a significant dose response (ANOVA p value < 0.01) in either normalization. Green points and quadrant labels indicate genes with a KDMM t-statistic negative and smaller or positive and larger than RPKM. These genes showed a greater statistical significance (larger −log 10 p values) using KDMM normalization. Red points and quadrant labels indicate genes with a RPKM t-statistic positive and greater or negative and smaller than KDMM. These genes showed greater statistical significance using RPKM normalization. Abbreviations: KDMM, Kernel Density Mean of M-component; RPKM, reads per kilobase per million.
Comparison of the Number of Significant Genes Identified by Each Technology and Normalization Method
With a p value cutoff as the significance criteria, microarrays generally produced more significant genes than RNA-seq at the lower doses (Table 2) . At the higher doses, the number of significant genes was comparable across the 2 technologies. Within a single technology, microarray normalization methods produced similar numbers of significant genes at all doses. Among the RNA-seq normalization methods, KDMM-nb produced more significant genes at the lower doses, whereas at the higher doses, RNA-seq normalization methods produced similar numbers of significant genes. With a fold-change cutoff as the significance criteria, RNA-seq generally produced more significant genes than microarrays at all doses. The exception to this trend was for the KDMM-nb normalization method which consistently produced lower numbers of significant genes among the RNA-seq normalization methods. Similarly, the PLIER normalization method consistently resulted in fewer significant genes when compared among the microarray normalization methods. When both fold-change and p value cutoffs were employed, microarrays and RNA-seq produced similar numbers of significant genes at the lower doses with RNA-seq producing more significant genes at the higher doses.
Overlap in Significant Genes Identified by Each Technology and Normalization Method
Using a combination of both fold-change and p value cutoffs as significance criteria, the overlap in significant genes was highly variable across normalization methods within a single technology and between the 2 technologies (Table 3) . Within microarrays, the overlap among significant genes for RMA and LOESS normalization was high and ranged between 78.3% and 89.1%. In contrast, the overlap between PLIER at the other 2 microarray normalization methods was relatively low and ranged between 19.0% and 40.4%. At the highest dose where the number of significant genes is maximal, the overlap ranged from 28.6% to 28.9%. Within RNA-seq, the overlap among significant genes was generally moderate and ranged from 26.3% to 67.3%. At the highest dose, the overlap ranged from 37.5% to 40.7%. In comparing across technologies, the average overlap was 27.4%. At the highest dose, the overlap ranged from 16.1% to 36.2%, with an average of 28.7%. For the more common microarray and RNA-seq normalization methods, the overlap was typically between 30% and 40% at the highest dose. The overlap in significant genes by each criterion separately is provided in Supplementary File 4.
Confirmation of Significant Genes Identified by Each Technology Using qRT-PCR
Genes were selected for qRT-PCR analyses using the ANOVA results for the highest treatment dose (400 mg/kg-day) in order to maximize the number of differentially expressed genes. Significant genes were defined based on statistical significance (FDR < 0.05) in all 3 normalization methods or statistical significance (FDR < 0.05) in all 3 normalization methods and fold change > 1.5 in 2 of the 3 normalization methods. Due to the compression of fold-change values by the PLIER microarray normalization method and KDMM-nb RNA-seq normalization method, these normalization methods were disregarded when assessing fold change. Three sets of significant genes were evaluated. The first set was significant by microarray analysis and not significant by RNA-seq analysis. A total of 41 The number of significant genes in each technology based on the total gene set of 11 403 Ensembl Gene IDs on the microarray and the 9399 Ensembl Gene IDs that had a minimum RNA-seq read count > 10 in all 30 samples. genes met this criterion for FDR < 0.05 and 11 genes met this criterion for FDR < 0.05 and fold change > 1.5. The second set was significant by RNA-seq analysis and not significant by microarray analysis. A total of 24 genes met this criterion for FDR < 0.05 and 12 genes met this criterion for FDR < 0.05 and fold change > 1.5. The third set was significant by RNAseq analysis and microarray analysis. A total of 24 genes met this criterion for FDR < 0.05 and 18 genes met this criterion for FDR < 0.05 and fold change > 1.5. Of the 41 genes that were statistically significant only in microarrays, 27% were confirmed by qRT-PCR. Of the 11 genes that were both statistically significant and significant by fold change only in microarrays, 100% were confirmed by qRT-PCR (Fig. 3) . Similarly, of the 24 genes that were statistically significant only by RNA-seq, 50% were confirmed by qRT-PCR. Of the 12 genes that were both statistically significant and significant by fold change only by RNA-seq, 100% were confirmed by qRT-PCR. All of the genes (100%) that were statistically significant or statistically significant and significant by fold change by both microarray and RNA-seq were confirmed by qRT-PCR.
Comparison of the Number of Significant Genes Identified by RNA-Seq and Microarrays Relative to Sequencing Depth
To better understand the impact of sequencing depth, artificial RNA-seq data sets were created by random downsampling of the original mapped read data sets. A total of 4 downsampled RNA-seq data sets were created of 15, 10, 5, and 2 million average mapped reads in addition to the original 21 million average mapped reads. In comparing the gene annotation characteristics of the downsampled data sets, the gain in the number of annotated genes with a read count > 10 is relatively large over the increase in read depth between 2 and 10 million reads (Table 4 ). The rate of gain in annotated genes falls off above 10 million reads. Even at an average read depth of 21 million reads, only 41% of annotated genes were detected. To evaluate the sequencing depth required to identify an equivalent number of differentially expressed genes relative to microarrays, the number of significant genes by RNA-seq was determined at different sequencing depths and divided by the number of significant genes identified by microarrays normalized using RMA. The RMA normalization was chosen as the basis set because it represents one of the most commonly employed methods for normalization in the microarray field. Using only a p value cutoff as the significance criteria, an equivalent number of significant genes was not consistently achieved across doses even at the full sequencing depth of 21 million average reads (Fig. 4) . In contrast, using only a fold-change cutoff as the significance criteria, RNA-seq consistently identified more significant genes than microarrays at a sequencing depth above 2 million average reads when normalized by either RPKM or KDMM. When normalized by KDMM-nb, RNA-seq did not consistently identify an equivalent number of significant genes at even the full sequencing depth. Finally, when using both a fold-change and p value cutoff as the significance criteria, RNA-seq consistently identified an equivalent number of genes as microarrays at a sequencing depth of approximately 5 million reads when normalized by either RPKM or KDMM.
Overlap in Enriched Pathways Identified by Each Technology and Normalization Method
To better understand how these technologies and normalization methods can lead to unique or similar conclusions as to the biological effects of the toxicant, pathway enrichment FiG. 3 . Proportion of significantly differentially expressed genes by each technology confirmed by qRT-PCR. Differentially expressed genes were defined based on statistical significance (FDR < 0.05) in all 3 normalization methods or statistical significance (FDR < 0.05) and fold change > 1.5 in 2 of the 3 normalization methods. For microarrays only, 41 genes were selected as statistically differentially expressed (FDR < 0.05) using all 3 normalization methods and not by RNA-seq (gray bar). A total of 11 genes were selected as significant only in microarray by FDR < 0.05 and fold change > 1.5 (black bar). For RNA-seq only, 24 genes were selected as statistically differentially expressed (FDR < 0.05) using all 3 normalization methods and not by microarrays (gray bar). A total of 12 genes were selected as significant only in microarray by FDR < 0.05 and fold change > 1.5 (black bar). For both technologies, 24 genes were selected as significant in both microarrays and RNA-seq (FDR < 0.05) for all associated normalization methods (gray bar), whereas 18 genes were selected as significant in both by FDR < 0.05 and fold change > 1.5 (black bar). The respective genes were analyzed by qRT-PCR, and the proportion confirmed showed differential expression in the same direction (ie, up-or downregulated) with statistical significance (p < 0.01) based on one-sided t-test. Abbreviations: FDR, false discovery rate; qRT-PCR, quantitative reverse transcription-PCR. 393 analysis was performed for each technology and normalization method on all genes significant by p value < 0.01 and fold change > 1.5 or < −1.5 in at least 1 dose. The total number of genes used in the enrichment analysis was 736 genes for RMA, 738 genes for LOESS, 205 genes for PLIER, 1066 genes for RPKM, 846 genes for KDMM, and 394 genes for KDMM-nb. Pathways significantly enriched (FDR < 0.05) in at least 1 technology or normalization were hierarchically clustered based on their −log p value for enrichment (Fig. 5) .
The results showed that the RNA-seq normalization methods KDMM and RPKM cluster together, the microarray normalization methods RMA and LOESS cluster together, and the microarray PLIER and RNA-seq KDMM-nb normalization methods cluster together. RNA-seq and RPKM normalization produced more significantly enriched pathways but also had the most genes for input in the analysis. Enrichment in developmental, immune-related, cytoskeletal, cell adhesion, and a number of other signal transduction pathways were uniquely observed among the RNA-seq KDMM and RPKM normalization methods. Fewer pathways were enriched in the microarray normalization methods, and none were unique. Among the pathways in common across both technologies and all normalizations, significant enrichment was observed in activation of the constitutive adrostane receptor (CAR), glutathione metabolism, and nuclear factor erythroid 2-related factor 2 (NRF2) activation. Several additional pathways were commonly enriched in RNA-seq KDMM and RPKM normalization methods and the microarray RMA and LOESS normalization methods including TGF-β regulation of cell proliferation, stellate cell activation, and transcriptional regulation of amino acid metabolism.
Comparison of Dose-Response Characteristics Across Technologies and Normalization Methods
Dose-response characteristics of the different technologies and normalization methods were evaluated using both gene-and FiG. 4 . Proportion of significantly differentially expressed genes by RNA-seq at different sequencing depths relative to microarrays normalized using RMA. The light gray bars represent the proportion of significantly differentially expressed genes relative to microarrays normalized using RMA based only on statistical significance at p < 0.01. The black bars represent the proportion of significantly differentially expressed genes relative to microarrays normalized using RMA based only on fold change at > 1.5 or < −1.5. The dark gray bars represent the proportion of significantly differentially expressed genes relative to microarrays normalized using RMA based on both p < 0.01 and fold change at > 1.5 or < −1.5. The x-axis lists the proportion of differentially expressed genes at each dose of bromobenzene (400, 300, 200, 100, and 25 mg/kg-day) and each sampling depth of RNA-Seq (Original, 15, 10, 5, and 2 million). The top, middle, and bottom set of bar graphs were RNA-Seq data normalized by RPKM, KDMM, and KDMM-nb, respectively. Abbreviations: KDMM, Kernel Density Mean of M-component; RMA, robust multiarray average; RPKM, reads per kilobase per million.
pathway-based BMD values. On a gene basis, BMD values were calculated for genes showing dose-response behavior (p < 0.01) with each technology and normalization method except KDMM-nb. KDMM-nb was not evaluated because the negative binomial transformation is performed during the ANOVA modeling. The genes were filtered for BMD values less than the highest dose and fit p values > 0.1. Scatter plots of each pairwise comparison were constructed (Fig. 6 top) . Within microarrays, the gene-based BMD values showed a general linear relationship with correlation coefficients for the different pairwise comparisons ranging from 0.843 to 0.921. Within RNA-seq, the correlation coefficient for RPKM and KDMM was 0.532. In comparing across technologies, the correlation coefficients ranged from 0.287 for LOESS and RPKM to 0.406 for RMA and KDMM. For most of the comparisons, the gene-based BMD values were most divergent at the higher doses while generally converging at the lower doses. The distributional characteristics were similar both within and across technologies (Fig. 6 bottom) . The median gene-based BMD values ranged from 236.48 to 267.46 mg/kg-day while the minimum BMD values ranged from 10.08 to 18.32 mg/kgday. In general, the gene-based BMD values were lower for microarrays than for RNA-seq.
Similar to that observed for the −log p values, there was a bifurcation in the gene-based BMD values between the RNAseq normalization methods. Further investigation showed that the 2 populations of BMD values (Fig. 6 , KDMM vs RPKM) corresponded to the overall direction of the dose response for those genes (ie, positive or negative slope). A pairwise comparison of slope values highlighted the breakdown of the 2 populations (Fig. 7) . The red data points correspond to the genes with a BMD value greater for RPKM than KDMM normalization, whereas the black data points correspond to genes with a BMD value greater for KDMM than RPKM. Genes showing a dose-dependent downregulation tended to have a steeper negative slope in KDMM relative to RPKM, whereas upregulated genes tended to have a steeper positive slope in RPKM relative to KDMM.
On a pathway basis, median BMD values were estimated for pathways with at least 5 genes with a BMD less than the highest dose and goodness-of-fit p value > 0.1. Scatter plots of each pairwise comparison were constructed (Fig. 8 top) . Within microarrays, the pathway-based BMD values showed a general linear relationship with correlation coefficients for the different pairwise comparisons ranging from 0.746 to 0.848. Within RNA-seq, the correlation coefficient for RPKM and KDMM was 0.332, which was much lower than the genebased BMD correlation. In comparing across technologies, the correlation coefficients ranged from 0.191 for PLIER and RPKM to 0.432 for PLIER and KDMM. The distributional characteristics were similar both within and across technologies (Fig. 8 bottom) . The median pathway-based BMD values ranged from 208.86 to 273.23 mg/kg-day, whereas the minimum BMD values ranged from 56.74 to 80.11 mg/kg-day.
The gene-based BMD values are a function of both the mean responses across doses and the estimate of variability in the control population. To better understand which of these components were responsible for the differences observed in the BMD values, pairwise correlation coefficients were calculated for mean expression for each gene as a function of dose. The pairwise correlations were calculated for only those genes with significant dose-response behavior (p < 0.01). For the mean expression values, a high degree of correlation was observed both within and between technologies (Fig. 9 top) . For microarrays, ~99% of the genes had a pairwise correlation of ≥ 0.9, whereas for RNA-seq ~85% of the genes had a correlation of ≥ 0.9. Across the 2 technologies, 75%-80% of the genes had pairwise correlations of ≥ 0.7.
For the gene-based variability in the control population, scatter plots of the coefficients of variation (CV) in the control animals were constructed for each pairwise comparison (Fig. 9  bottom) . Within microarrays, the CVs showed a linear relationship between RMA and LOESS with a correlation coefficient of 0.988, but PLIER normalization resulted in more disparate and often lower shifted CV values. Within RNA-seq, the CVs were linearly related with a correlation coefficient for RPKM and KDMM of 0.884. In comparing across technologies, the correlation coefficients ranged from 0.197 for PLIER and RPKM to 0.614 for RMA and KDMM.
To evaluate potential effects of expression level on estimates of variability, the normalized gene-based expression values in the control samples were broken into quintiles, and the distribution of CV values was represented using box and whisker plots (Fig. 10) . Within microarrays, RMA and LOESS showed similar profiles with tighter distributions in CV values in the first and fifth quintiles and expanded distributions in the second, third, and fourth quintiles. The lower and upper edges of the boxes that represent the 25th and 75th percentiles generally ranged from 0.12 to 0.25 for the middle quintiles, respectively. For the PLIER normalization method, the distribution of CV values showed a monotonic increase with expression level. The 25th and 75th percentiles were significantly compressed compared with the other microarray normalization methods and ranged from 0.07 to 0.17 for the fifth quintile, respectively. Within RNA-seq, both the RPKM and KDMM normalization methods showed a monotonic decrease in the distribution of CV values with expression level. In the lowest expression quintile, the 25th and 75th percentiles ranged from 0.2 to 0.45, respectively. At high levels of expression, the 25th and 75th percentiles ranged from 0.15 to 0.25, respectively.
DisCussiON
For over a decade, gene expression experiments in toxicology have relied on microarrays as the primary tool for collecting transcriptome-scale data (Chen et al., 2012) . Microarray studies allow for the simultaneous measurement of expression levels for tens of thousands of genes, providing a comprehensive evaluation of chemically induced perturbations in cellular functions. Due to both the perceived limitations of microarray technology as well as the rapidly decreasing costs of DNA sequencing, RNA-seq has become a popular replacement for microarrays; however, the full potential of RNA-seq as a replacement for microarrays in toxicology is not yet clear. Most published comparisons of RNA-seq and microarrays have not included dose-response evaluation (Su et al., 2011; van Delft et al., 2012) . In this study, a comprehensive comparison of gene expression data was conducted for microarrays and RNA-seq in a dose-response study design. The effects of different normalization methods were also evaluated within each technology.
At a high level, the rank order of the unnormalized and normalized expression levels of the individual genes was generally correlated between the 2 technologies. Although certain normalization methods such as PLIER for microarrays and KDMM-nb for RNA-seq compressed observed fold changes in expression, the fold-change values were generally correlated between the 2 technologies. The degree of correlation of fold-change values observed in our study was similar or slightly higher than that observed in a previous comparison of microarrays and RNAseq measuring gene expression changes in HepG2 cells treated with benzo[a]pyrene (van Delft et al., 2012) . When fold change was used as basis for significance, RNA-seq generally produced more significant genes than microarrays at all dose levels except when a negative binomial transformation was applied. When p value was used as the basis for significance, microarrays generally showed more significant genes than RNA-seq at the lower doses but showed comparable numbers of significant genes at the higher doses. When both fold change and p values were used as the basis for significance, comparable numbers of significant genes were observed at lower doses, but RNA-seq FiG. 7 . Scatter plot of the slopes of linear models fit to the RNA-seq dose-response data normalized using RPKM and KDMM. The subset of genes displayed are those with BMD for both data sets (BMD less than the highest dose and a fit p value > 0.1) and a statistically significant dose response (ANOVA p value < 0.01) in either data set. The red line is the regression line through the scatter plot (KDMM = −0.061 + 1.016 × RPKM, r 2 adjusted = 0.996). The dashed green represents unity. Two extreme values were excluded from the plot for convenience of scale (Gstp: RPKM slope = 1.282, KDMM slope = 1.327, and Obp3: RPKM slope = −1.588, KDMM slope = −1.667). The color coding of the data points correspond to the split observed in the RPKM and KDMM BMD scatter plot (Fig. 6) , with red indicating genes below the diagonal (genes with RPKM BMD > KDMM BMD) and black indicating those genes above the diagonal (genes with RPKM BMD < KDMM BMD). Abbreviations: BMD, benchmark dose; KDMM, Kernel Density Mean of M-component; RPKM, reads per kilobase per million.
showing more significant genes at the higher doses. Our study contrasts with the comparison of differentially expressed genes in HepG2 cells, which suggested that RNA-seq produced dramatically more differentially expressed genes than microarrays (van Delft et al., 2012) . However, the earlier study used a combination of fold change and FDR corrected p values making a true comparison with our study difficult.
The overlap in differentially expressed genes defined using both a fold-change and p value cutoff was highly dependent on the normalization method used for each technology. On average, the overlap was 27.4%. In general, the greatest overlap was observed when RMA or LOESS was used to normalize the microarray data and RPKM or KDMM was used to normalize the RNA-seq data. When these normalization methods were employed, the overlap was typically 30% to 40% at the highest dose, which is consistent with that reported in a previous study comparing RNA-seq and microarrays for aristolochic acid-induced expression changes in the rat kidney (Su et al., 2011) .
One potential reason for the limited overlap in differentially expressed genes was the lack of correlation in −log p values. Within the RNA-seq normalization methods, a relatively low correlation in −log p values was observed. This was primarily due to the differential effects of RPKM and KDMM normalization across the range of read counts. In upregulated genes with higher count numbers, RPKM normalization tended to inflate the estimates of fold change and statistical significance, whereas KDMM decreased estimates of fold change and statistical significance. However, the effect of KDMM normalization on fold change for these genes was much less apparent that that observed with RPKM. In downregulated genes with lower count numbers, the opposite trends occurred for RPKM and KDMM normalization. Based on these results, RPKM would appear to be less appropriate as an RNA-seq normalization method. A previous report also reported similar poor performance from the RPKM method due to the way the data are normalized using the total number of mapped reads (Wagner et al., 2012) .
Given the relatively low overlap in differentially expressed genes, a third technology, qRT-PCR, was used to better understand which technology more consistently reported true differential expression. Genes were selected for qRT-PCR analyses based on statistical significance (FDR < 0.05) or statistical significance (FDR < 0.05) and fold change > 1.5. Genes that were statistically significant only in microarrays showed a 27% confirmation rate, whereas those that were both statistically significant and significant by fold change showed 100% confirmation. Similarly, genes that were statistically significant only by RNA-seq showed a 50% confirmation rate, whereas those that were both statistically significant and significant by fold change showed 100% confirmation. All of the genes (100%) that were statistically significant or statistically significant and significant by fold change by both microarray and RNA-seq were confirmed by qRT-PCR. The increased confirmation rate when a fold-change cutoff was employed was not surprising because previous studies have demonstrated a much greater concordance between microarrays and qRT-PCR when foldchange values were used to select differentially expressed genes (Shi et al., 2008) . However, the data also suggest that neither technology is necessarily better at identifying differentially expressed genes; each technology identifies specific groupings of differentially expressed genes while missing others.
One question that has been raised in replacing microarrays with RNA-seq is the depth of sequencing required to achieve comparable results. This consideration arises because costs associated with RNA-seq are directly related to the depth of sequencing. In our study, no spike-in samples or specified ratio mixes were used. Therefore, the true differential expression of each gene is not known. Instead, the number of significant differentially expressed genes for each technology was used as the basis for comparison. Using this metric, the number of significant genes by RNA-seq was determined at different sequencing depths created by random downsampling of the original data set. The number of significant genes in each downsampled data set was divided by the number of significant genes identified by microarrays normalized using RMA. The RMA normalization was chosen as the basis set because it represents one of the most commonly employed methods for normalization in the microarray field. Using only a p value cutoff, an equivalent number of significant genes was not consistently achieved across doses even at the full sequencing depth. Conversely, using only a fold-change cutoff, RNA-seq consistently identified more significant genes at a sequencing depth above 2 million average reads when normalized by either RPKM or KDMM. A negative binomial transformation of the KDMM normalization reduced the number of significant genes at even the full sequencing depth. When using both a fold-change and p value cutoff as the significance criteria, RNA-seq consistently identified an equivalent number of genes as microarrays at a sequencing depth of approximately 5 million reads when normalized by either RPKM or KDMM. The estimate of 5 million reads is greater than an earlier study using human samples which indicated that read depths of as little as 2 million mapped reads should be sufficient to match microarray sensitivity in detecting differentially expressed genes with a fold change of 2 or greater (Illumina, 2011) . Aside from sensitivity in identifying differentially expressed genes, read depth also determines the proportion of known genes detected in a given sample. Although RNA-seq has the potential to detect all transcripts present in a sample at sufficient read depth, the rate of discovery of new features is asymptotic. In our study, we observed an increase of approximately 1400 new genes between 5 and 10 million reads and 300 new genes between 15 and 20 million reads. The rate of new gene discovery in our study significantly diminished above 10 million reads. The rate of new gene discovery in our study is consistent with a previous study using human samples that showed the rate of new gene discovery was between 70 and 80 genes per million reads at a sequencing depth of 15-20 million reads (Tarazona et al., 2011) . Given that 5 million reads provides approximately the same number of differentially expressed genes as microarrays and the rate of new gene discovery diminishes above 10 million reads, our study suggests that the experimental design for a dose-response RNA-seq study should contain at least 5-10 million reads per sample.
In evaluating whether microarrays and RNA-seq provide differing or similar conclusions regarding the potential biological effects of a chemical, pathway enrichment results were compared across technologies and normalization methods. As expected, the pathway enrichment results were more similar within each technology than across technologies with the exception of the microarray PLIER and RNA-seq KDMM-nb normalization methods which clustered together. The RNA-seq methods produced more enriched pathways and many were unique to the technology, whereas the microarray methods produced fewer enriched pathways and almost none were unique. For example, enrichment in cytoskeletal remodeling and WNT signaling was uniquely observed among the RNA-seq KDMM and RPKM normalization methods. It is not clear whether RNA-seq provides greater biological insight into activation of these pathways or whether their enrichment was due to lack of false discovery correction in the input gene lists. Pathways commonly enriched across both technologies and all normalizations were CAR activation, glutathione metabolism, and NRF2 activation. This suggests that activation of CAR and oxidative stress or generation of reactive metabolites were robustly observed across the gene expression profiles and may be common molecular events in the toxicological response. The generation of oxidative stress or reactive metabolites is consistent with previous studies that observed that BRBZ is metabolized via mixed cytochrome P450s to reactive intermediates, such as 2,3-and 3,4-BB epoxides, that bind to tissue macromolecules (Colacci et al., 1985) . Also observed in the RNA-seq normalization methods KDMM and RPKM and the microarray normalization methods RMA and LOESS was a common enrichment in stellate cell activation and TGF-β mediated regulation of cell proliferation. This suggests that cell death, regenerative proliferation, and early fibrotic events may also be a part of the mode of action. However, no evidence of fibrosis or necrosis was observed at any dose in the histopathology (Dodd et al., 2013) .
To compare the ability to characterize dose-response changes in expression, BMD modeling was used to estimate a point of departure for each gene and pathway (Thomas et al., , 2013b . Previous studies have shown good concordance between transcriptional BMD values estimated using microarrays and traditional BMD values based on pathological lesions suggesting that they may be used as a basis for chemical risk assessment (Thomas et al., , 2013b . Among the gene-based BMD values, pairwise comparisons showed good agreement within microarray normalization methods; however, within RNA-seq, differences in the normalization method resulted in significant differences in BMD values for 2 populations of genes. Genes showing a dose-dependent downregulation tended to have a steeper negative slope with KDMM normalization relative to RPKM, whereas upregulated genes tended to have a steeper positive slope with RPKM normalization relative to KDMM. These differences appear to result from RPKM normalization inflating expression values for genes with dose-dependent increases in read count, while compressing expression values for genes with decreases in read counts (controls being equal). KDMM normalization tends to have the opposite effect although the observed data suggests that the impact was much less with KDMM. For application to doseresponse experiments, the current data suggest that RPKM normalization is less optimal and would lead to consistent bias in the estimation of gene-based BMD and BMDL values.
Across technologies, the gene-based BMD values showed only moderate correlation. The BMD values were most divergent at the higher doses while generally converging at the lower end of the dose-response curve. The best correlation was observed between RMA normalization for microarrays and KDMM normalization for RNA-seq with a correlation coefficient of 0.406. Apart from the pairwise correlation, the distributional characteristics of the gene-based BMD values were generally similar between technologies. The median gene-based BMD values were within 15%. At the lower end of the dose-response curve, the gene-based BMD values were marginally higher for RNA-seq with minimum BMD values of approximately 10 and 18 mg/kg-day for microarrays and RNAseq, respectively.
Similar to the gene-based BMD values, the pathway-based BMD values showed good agreement within microarray normalization methods, whereas the RNA-seq normalization methods showed only moderate correlation. Across technologies, the pathway-based BMD values also showed moderate correlation. The distributional characteristics of the pathwaybased BMD values were more divergent between technologies than the gene-based values. The upper and lower quartiles and median BMD values were consistently higher in the RNA-seq normalization methods compared with the microarray methods; however, the minimum pathway BMD values for RNAseq were lower at 56.74 and 76.33 mg/kg-day compared with microarray methods ranging from 78.26 to 80.11 mg/kg-day. By comparison, the apical noncancer point of departure at 13 weeks was 96.8 mg/kg-day for changes in absolute liver weight (Thomas et al., 2013b) .
The gene-based BMD values are a function of both the mean responses across doses and the estimate of variability in the control population. Based on pairwise correlation coefficients of the mean expression for each gene as a function of dose, the mean responses were highly correlated across technologies. Approximately 75%-80% of the genes had pairwise correlations of ≥ 0.7. In contrast, the estimates of the control variability were less correlated across technologies and were highly dependent on the normalization method used. For microarrays, the RMA and LOESS normalization methods showed a high degree of correlation in control CV values, whereas PLIER showed a lower correlation and resulted in consistently lower CV values. For RNA-seq, the CV values for RPKM and KDMM normalization methods showed a high correlation (.884), but the KDMM CV values were consistently lower. Across technologies, a moderate degree of correlation in CV values was observed except for the microarray data normalized with PLIER. The highest correlation across technologies was between RMA normalization for microarrays and KDMM for RNA-seq with a correlation coefficient of 0.614.
One possible factor in the lower correlation in estimates of control variability may be the relative expression level of the gene. Normalized expression values in the vehicle control samples were broken into quintiles, and the distribution of CV values was evaluated within each quintile. For microarrays, the distribution in CV values showed nonmonotonic changes with expression for the RMA and LOESS normalization methods. For these methods, the distributions of CV values were tighter for the first and fifth quintiles. One explanation for the behavior in the first quintile is that the background correction used in these methods overcompensates leading to a compression in the estimates of sample variability. For the PLIER microarray normalization method, a monotonic increase in range of CV values was observed with increasing expression. This relationship is counterintuitive because one would expect greater sample variability in genes with low expression. In part, this may be due to error model employed by PLIER that assumes error is proportional to the observed intensity rather than a background-subtracted intensity like that employed by RMA and LOESS. With RNA-seq, a monotonic decrease in the range of CV values with expression level was observed. Overall, the distribution of CV values was also greater for RNA-seq than for microarrays. The increased variability in control samples could explain why the RNA-seq BMD values were generally higher than those estimated by microarrays.
The overall assessment of using RNA-seq as a replacement for microarrays in dose-response studies is mixed. Although there was good concordance between the 2 technologies with regard to quantitative changes in expression (ie, fold change) and mean dose-response behavior, estimates of sample variability, statistical significance, and BMD values showed a lower degree of correlation. Specifically for toxicology and risk assessment, RNA-seq detected fewer statistically significant genes at lower doses, but more significant genes based on fold change except when a negative binomial transformation was applied. The gene-and pathway-based BMD values estimated by both technologies only showed a moderate degree of correlation. For the gene-based BMD values, RNA-seq generally had larger estimates of sample variance which may have resulted in higher BMD estimates. In part, the lower degree of correlation between the 2 technologies with regard to sample variance and BMD values may be due to differences in the dynamic range of each technology and the degree to which normalization methods correct genes at either end of the scale. The microarray normalization methods have had over a decade to mature, and the community has generally coalesced around a small number of generally well-behaved methods. In contrast, the RNA-seq normalization methods are still being developed, and better methods are required that provide robust normalization of technical variability across the relatively large dynamic range of count data, while still maintaining biological fidelity. Additional studies will also be needed to better understand the differences in the 2 technologies with respect to estimating sample variance and BMD values for application to risk assessment.
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